🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. 100U inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Hand-foot-mouth Disease

    phase 1 mab completed

    1 trial

  2. 610 30mg group

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Asthma

    phase 1 small molecule active

    1 trial

  3. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

  4. A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the bloodstream and is absorbed, modified and removed from the body when administered as a Subcutaneous Infusion Using a Syringe Pump and as an Intravenous Infusion in Healthy Adult Participants

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  5. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS

    Lacuna Pharma Pty Ltd

    alopecia areata

    phase 1 other active

    1 trial

  6. A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

    Celltrion Healthcare Australia Pty Ltd

    Completely Resected Stage IIB, IIC, and III Melanoma

    phase 1 other active

    1 trial

  7. A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  8. A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

    KYOWA KIRIN AUSTRALIA PTY LTD

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

  9. A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

    Lacuna Pharma Pty Ltd

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  10. A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  11. A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial

  12. A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Nervous System disease

    phase 1 other active

    1 trial

  13. A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

  14. A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Pharmacological Effects of PT00114 in Healthy Volunteers

    Protagenic Therapeutics, Inc.new

    Phase I study in healthy male and female volunteers. Intended indication: mood disorders

    phase 1 other active

    1 trial

  15. A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Selected Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  16. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  17. A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    Prelude Therapeutics Inc

    esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 1 other active

    1 trial

  18. A Phase 1 Trial Assessing Pharmacokinetics and Safety of CAM2056 (Semaglutide Subcutaneous Depot)

    Camurus Pty Ltd

    Body weight management

    phase 1 other active

    1 trial

  19. A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    phase 1 other active

    1 trial

  20. A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  21. A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  22. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial

  23. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease

    AstraZeneca AB

    Chronic Kidney disease, Atherosclerotic Cardiovascular Disease

    phase 1 other active

    1 trial

  24. A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources